האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - elebrato ellipta hija indikata bħala trattament manutenzjoni fil-pazjenti adulti ma moderat severi kronika eliminat pulmonari marda (copd) li m'humiex ittrattati adegwatament mill-għaqda tal-corticosteroid bin-nifs u a twila u jaġixxu β2-agonist.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - aġenti antineoplastiċi - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide, vilanterol trifenatate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - anoro ellipta huwa indikat bħala l-manutenzjoni bronkodilatur-kura biex ittaffi s-sintomi fil-pazjenti adulti bil-marda pulmonari ostruttiva kronika (copd).

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

substipharm - prasugrel - acute coronary syndrome; angina, unstable; myocardial infarction - aġenti antitrombotiċi - efient, ko amministrati bl-aċidu aċetilsaliċiliku (asa), huwa indikat għall-prevenzjoni ta ' avvenimenti ta ' atherothrombotic fil-pazjenti bl-sindromu coronary akuta (i. anġina instabbli, mhux-st-segment-elevazzjoni myocardial infarzjoni [ua / nstemi] jew st-segment-elevazzjoni myocardial infarzjoni [stemi]) li jkunu għaddejjin minn intervent coronary perkutanja (pci) ta ' primarja jew mdewma.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline trading services - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trelegy ellipta hija indikata bħala trattament manutenzjoni fil-pazjenti adulti ma moderat severi kronika eliminat pulmonari marda (copd) li m'humiex ittrattati adegwatament mill-għaqda tal-corticosteroid bin-nifs u a twila u jaġixxu β2-agonist.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - temybric ellipta huwa indikat bħala kura ta 'manteniment f'pazjenti adulti b'indeboliment moderat jew sever tal-marda pulmonari ostruttiva kronika (copd) li ma jkunux qed jiġu kkurati b'taħlita ta' kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2-agonist jew kombinazzjoni ta taġixxi fit-tul β2-agonist u li jaħdem fit-tul muskariniċi antagonist (għall-effetti fuq il-kontroll tas-sintomi u l-prevenzjoni tal-aggravar tal-attakki ara sezzjoni 5.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. trattament ta ' osteoporożi assoċjat ma sistemiku fit-tul terapija bi glukokortikojdi fil-nisa wara l-menopawża u f'irġiel f'riskju akbar ta'ksur. it-trattament tal-marda ta'paget ta ' l-għadam.

האיחוד האירופי - מלטית - EMA (European Medicines Agency)

actavis group hf - telmisartan, hydrochlorothiazide - essential hypertension - agents acting on the renin-angiotensin system, angiotensin ii antagonists and diuretics - trattament ta 'ipertensjoni essenzjali. actelsar hct kombinazzjoni b'doża fissa (40 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 25 mg hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata adegwatament fuq actelsar hct 80 mg / 12. 5 mg (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) jew adulti li qabel kienu stabbilizzati fuq telmisartan u hydrochlorothiazide mogħtija separatament.